Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБОУ ВПО Ростовский государственный медицинский университет. 344022, Россия, Ростов-на-Дону, пер. Нахичеванский, д. 29
Список исп. литературыСкрыть список 1. Арушанян Э.Б. Антистрессорные возможности эпифизарного мелатонина. В кн.: Мелатонин в норме и патологии. М., 2004; с. 198–222. / Arushanian E.B. Antistressornye vozmozhnosti epifizarnogo melatonina. V kn.: Melatonin v norme i patologii. M., 2004; s. 198–222. [in Russian] 2. Арушанян Э.Б. Мелатонинергический антидепрессант вальдоксан. Эксперим. и клин. фармакология. 2011; 74 (7): 41–5. / Arushanian E.B. Melatoninergicheskii antidepressant val'doksan. Eksperim. i klin. farmakologiia. 2011; 74 (7): 41–5. [in Russian] 3. Бочкарев В.К., Панюшкина С.В. Электроэнцефалографические исследования при пограничных состояниях. Пограничные психические расстройства. Под ред. Ю.А.Александровского. М.: Медицина, 2000. / Bochkarev V.K., Paniushkina S.V. Elektroentsefalograficheskie issledovaniia pri pogranichnykh sostoianiiakh. Pogranichnye psikhicheskie rasstroistva. Pod red. Iu.A.Aleksandrovskogo. M.: Meditsina, 2000. [in Russian] 4. Левин Я.И. Мелатонин (мелаксен) в терапии инсомнии. РМЖ. 2005; 13 (7): 498–501. / Levin Ia.I. Melatonin (melaksen) v terapii insomnii. RMZh. 2005; 13 (7): 498–501. [in Russian] 5. Медведев В.Э. Терапия непсихотических депрессий в рамках инволюционной истерии (опыт применения Вальдоксана). Психиатрия и психофармакотерапия. 2011; 13 (4): 14–8. / Medvedev V.E. Terapiia nepsikhoticheskikh depressii v ramkakh involiutsionnoi isterii (opyt primeneniia Val'doksana). Psychiatry and Psychopharmacotherapy. 2011; 13 (4): 14–8. [in Russian] 6. Медведев В.Э., Гушанская Е.В., Тер-Исраелян А.Ю. Терапия депрессий с явлениями ангедонии (опыт применения Вальдоксана). Психиатрия и психофармакотерапия. 2014; 16 (3): 45–9. / Medvedev V.E., Gushanskaia E.V., Ter-Israelian A.Iu. Terapiia depressii s iavleniiami angedonii (opyt primeneniia Val'doksana). Psychiatry and Psychopharmacotherapy. 2014; 16 (3): 45–9. [in Russian] 7. Зенков Л.Р. Клиническая электроэнцефалография с элементами эпилептологии. М.: МЕДпресс-информ, 2004. / Zenkov L.R. Klinicheskaia elektroentsefalografiia s elementami epileptologii. M.: MEDpress-inform, 2004. [in Russian] 8. Поворинский А.Г., Заболотных В.А. Пособие по клинической электроэнцефалографии. М.: Наука, 1987. / Povorinskii A.G., Zabolotnykh V.A. Posobie po klinicheskoi elektroentsefalografii. M.: Nauka, 1987. [in Russian] 9. Хадзегова Ф.Р. Особенности состояния сердечно-сосудистой системы, вегетативного и психологического статуса у пациентов с синдромом раздраженного кишечника. Автореф. … канд. мед. наук. М., 2008. / Khadzegova F.R. Osobennosti sostoianiia serdechno-sosudistoi sistemy, vegetativnogo i psikhologicheskogo statusa u patsientov s sindromom razdrazhennogo kishechnika. Avtoref. … kand. med. nauk. M., 2008. [in Russian] 10. Andrisano C, Chiesa A, Serretti A. Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol 2013; 28: 33–45. 11. Barsky AJ, Orav EJ, Bates DW. Somatization Increases Medical Utilization and Costs Independent of Psychiatric and Medical Comorbidity. Arch Gen Psychiatry 2005; 62: 903–10. 12. Bazanova OM, Aftanas LI. Individual measures of electroencephalogram alpha activity and non-verbal creativity. Neurosci Behav Physiol 2008; 38 (3): 227–35. 13. Bruder GE, Sedoruk JP, Stewart JW et al. EEG alpha measures predict therapeutic response to an SSRI antidepressant: Pre and post treatment findings. Biol Psychiatry 2008; 12 (63): 1171–7. 14. Cantero JL, Atienza M, Stickgold R et al. Sleep-dependent theta oscillations in the human hippocampus and neocortex. J Neurosci 2003; 23: 10897–903. 15. Dubovsky SL, Warren C. Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin Investig Drugs 2009; 18 (10): 1533–40. 16. Eser D, Baghai NC, Moller HJ. Evidence of agomelatinés antidepressant efficacy: the key points. Int Clin Psychopharmacol 2007; 22 (2): 15–9. 17. Im CH, Hwang HJ, Che H, Lee S. An EEG-based real-time cortical rhythmic activity monitoring system. Physiol Meas 2007; 9 (28): 1101–13. 18. Itil TM. Quantitative pharmaco-electroencephalography. Psychotropic Drugs and the Human EEG. Mod Probl Pharmacopsych 1974; 8: 43–75. 19. Itil TM. The discovery of psychotropic drugs by computer analyzed cerebral bioelectrical potentials (CEEG). Drug Dev Res 2004; 1 (4): 373–407. 20. Hanoum N, Mocaer E, Boyer PA. Differential effects of the novel antidepressant (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology 2004; 47: 515–26. 21. Herzallah MM, Moustafa AA, Natsheh JY et al. Learning from negative feedback in patients with major depressive disorder is attenuated by SSRI antidepressants. Front Integr Neurosci 2013; 7: 1–9. 22. Kasper S, Hamon M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiat 2009; 10 (2): 117–26. 23. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of MDD. CNS Drug 2010; 24: 479–99. 24. Millan MJ, Gobert A, Lejeune F. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954–64. 25. Nakao M, Shinozaki Y, Ahern DK, Barsky AJ. Anxiety as a predictor of improvements in somatic symptoms and health anxiety associated with cognitive-behavioral intervention in hypochondriasis. Psychother Psychosom 2011; 80: 151–8. 26. Nemeroff CB, Thase ME. A double-blind, placebocontrolled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res 2007; 41: 351–60. 27. Quera Salva MA, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol Clin Exp 2010; 25: 222–9. 28. Quera Salva MA, Hartley S, Barbot F et al. Circadian rhythms, melatonin and depression. Curr Pharm Des 2011; 17 (15): 1459–70. 29. Srinivasan V, Smits M, Spence W. Melatonin in mood disorders. World J Biol Psychiat 2006; 7 (3): 138–52. 30. Stahl SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatoninergic agonism. Int J Neuropsycopharmacol 2007; 10: 575–8. 31. Suffin SC, Emory WH, Gutierrez G. A QEEG database method for predicting pharmacotherapeutic outcome in refractory major depressive disorders. Am Physic Sur 2007; 4 (12): 104–8.